Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) just unveiled an update.
ASKA Pharmaceutical Holdings Co., Ltd. reported its consolidated financial results for FY2024, showing a slight increase in net sales by 2.1% to 64,139 million yen. However, the company experienced a decline in operating profit by 18% and ordinary profit by 21.7%, with profit attributable to owners of the parent dropping by 32.4%. Despite these declines, the company increased its annual dividends per share from 40 yen to 55 yen, indicating a commitment to returning value to shareholders. The forecast for FY2025 shows an optimistic outlook with expected growth in net sales and profits.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily involved in the pharmaceutical industry. The company focuses on the development and sale of pharmaceutical products, catering to various healthcare needs.
Average Trading Volume: 47,952
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen61.9B
For an in-depth examination of 4886 stock, go to TipRanks’ Stock Analysis page.